ClinicalTrials.gg
RecruitingNCT07744009NIA-HeartUpdated Aug 7, 2026

Nonintubated Anesthesia for Adult Cardiac Surgery With Cardiopulmonary Bypass

An interventional study of Nonintubated Anesthesia Group and Conventional Anesthesia Group in Valve Disease, Heart and CABG, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Valve Diseases with a site in China — 28 open to participants now, 30 under way, none of them phase 3. Heart Valve Diseases · China.

Planned enrollment
13th of 34
300 · median 200
Started
2026
with 6 others
No phase
27 of 69
10 open now
Primary completion
2028-07
later than 24 of 29 live
Registered
66th of 69
by date

Among the 69 studies in Heart Valve Diseases with a site in China, this one is the 13th largest by planned enrollment of the 34 interventional ones that give a count, is one of 7 that started in 2026, is one of 27 with no phase, reaches primary completion later than 24 of the 29 other live ones, and was the 66th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

28 of the 69 studies in Heart Valve Diseases with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Valve Diseases with a site in China, or all of them as a file.
02

Study summary

The goal of this prospective, multicenter, randomized clinical trial is to learn whether a nonintubated supraglottic airway anesthesia strategy with early restoration of spontaneous breathing can reduce postoperative pulmonary complications and improve early recovery in adults undergoing elective cardiac surgery with cardiopulmonary bypass.

The main questions it aims to answer are whether, compared with conventional endotracheal fast-track anesthesia, the nonintubated strategy can reduce pulmonary complications within 30 days after surgery, reduce the need for postoperative invasive mechanical ventilation and other respiratory support, and shorten the time spent in the intensive care unit.

Participants will be randomly assigned to undergo cardiac surgery using either a standardized nonintubated supraglottic airway anesthesia strategy with early restoration of spontaneous breathing or a conventional endotracheal fast-track anesthesia strategy. Both groups will receive standardized perioperative care, with objective criteria for airway removal and readiness for discharge from the intensive care unit. Endotracheal intubation or escalation of respiratory and circulatory support will be performed whenever clinically necessary.

Participants will be followed from screening through hospitalization, at 30 days after surgery, and for up to 1 year. Routine perioperative data and key postoperative outcomes, including pulmonary complications, respiratory support, intensive care unit stay, major organ complications, safety events, recovery, rehospitalization, and survival, will be collected.

Read the detailed description

Purpose:

Adults undergoing cardiac surgery with cardiopulmonary bypass are at risk of postoperative pulmonary complications, prolonged respiratory support, and delayed recovery. This prospective, multicenter, randomized clinical trial (NIA-CPB) aims to evaluate the clinical effectiveness and perioperative safety of a nonintubated supraglottic airway anesthesia strategy with early restoration of spontaneous breathing. The strategy is designed to reduce exposure to endotracheal intubation and invasive mechanical ventilation while maintaining adequate oxygenation, ventilation, hemodynamic stability, and surgical conditions.

The study will compare this strategy with conventional endotracheal fast-track anesthesia in adults undergoing elective cardiac surgery with cardiopulmonary bypass. The primary objective is to determine whether the nonintubated strategy reduces pulmonary complications within 30 days after surgery. Additional objectives include evaluating postoperative invasive mechanical ventilation, other forms of respiratory support, intensive care unit stay, recovery, major organ complications, and safety.

Study Design and Methods:

NIA-CPB is a multicenter, parallel-group, randomized clinical trial that will enroll approximately 400 adults aged 18 years or older who are scheduled to undergo elective cardiac valve surgery or coronary artery bypass grafting with cardiopulmonary bypass. Participants will be randomly assigned in a 1:1 ratio to either the nonintubated anesthesia group or the conventional endotracheal anesthesia group.

Participants assigned to the intervention group will receive a standardized perioperative anesthesia strategy using a supraglottic airway without routine endotracheal intubation and with early restoration of spontaneous breathing when clinically feasible. Participants assigned to the control group will receive conventional endotracheal fast-track anesthesia. Both groups will receive standardized perioperative care and will be assessed using the same objective physiologic criteria for airway removal and readiness for discharge from the intensive care unit. Participants in the control group may undergo extubation in the operating room when the predefined criteria are met.

Patient safety will take priority over adherence to the assigned airway strategy. Predefined clinical criteria will guide conversion to endotracheal intubation or escalation of respiratory or circulatory support when necessary, including inadequate oxygenation or ventilation, hemodynamic instability, airway device failure, suspected aspiration, major bleeding, or surgical requirements.

The primary endpoint is a composite of pulmonary complications occurring within 30 days after surgery, including prolonged postoperative invasive mechanical ventilation, unplanned re-intubation, tracheostomy, moderate or severe acute respiratory distress syndrome, and pneumonia. The individual components of the composite endpoint will also be reported. Additional clinical and safety outcomes will be collected during hospitalization and follow-up.

Participants will be followed from screening through hospitalization, at 30 days after surgery, and for up to 1 year. An independent committee blinded to treatment assignment will assess key pulmonary outcomes using predefined criteria.

Anticipated Results:

The investigators hypothesize that, compared with conventional endotracheal fast-track anesthesia, the nonintubated supraglottic airway strategy with early restoration of spontaneous breathing will reduce postoperative pulmonary complications, decrease the need for invasive mechanical ventilation and other advanced respiratory support, and support earlier recovery from intensive care.

The study is expected to provide multicenter randomized evidence regarding the effectiveness, feasibility, and safety of this perioperative anesthesia strategy in adults undergoing cardiac surgery with cardiopulmonary bypass. The findings may help inform future perioperative airway and respiratory management practices in adult cardiac surgery.

03

Conditions studied

  • Valve Disease, Heart
  • CABG

Browse trials for

Keywords

  • Enhanced recovery after surgert
  • cardiac surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older, regardless of sex
  • Scheduled to undergo elective cardiac valve surgery with cardiopulmonary bypass
  • Considered eligible for either the non-intubated supraglottic airway anesthesia with early restoration of spontaneous breathing (NIA) strategy or the conventional anesthesia strategy, based on a joint preoperative assessment by the anesthesiology and cardiac surgery teams
  • Relatively stable vital signs and able to complete the required perioperative assessments and follow-up
  • Willing to participate in the study and able to provide written personally or through a legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Emergency or urgent cardiac surgery
  • Severe pulmonary infection, severe respiratory failure, or another preoperative condition that clearly precludes use of the NIA strategy
  • Severe preoperative hemodynamic instability requiring high-dose vasoactive medications or mechanical circulatory support
  • Known difficult airway, high risk of aspiration, or another anesthetic to the NIA strategy
  • Severe hepatic, renal, or neurological disease that may substantially affect the assessment of perioperative outcomes
  • Pregnant or breastfeeding
  • Previous or concurrent participation in another interventional clinical trial that may affect the results of this study, if the participant remains within the relevant intervention or carryover period
  • Any other protocol-specified clinical condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Nonintubated Anesthesia Group

    Participants assigned to this group will receive a standardized nonintubated supraglottic airway anesthesia strategy with early restoration of spontaneous breathing during cardiac surgery with cardiopulmonary bypass. Endotracheal intubation or escalation of respiratory and circulatory support will be performed when clinically necessary. Participants will receive standardized perioperative care and will be assessed using predefined physiologic criteria for airway removal and intensive care unit discharge readiness.

    Procedure: Nonintubated Anesthesia Group

  • Active comparator
    Conventional Anesthesia Group

    Participants assigned to this group will receive standardized conventional general anesthesia with endotracheal intubation and lung-protective mechanical ventilation during cardiac surgery with cardiopulmonary bypass. Extubation or escalation of respiratory and circulatory support will be performed when clinically appropriate. Participants will receive standardized perioperative care and will be assessed using the same predefined physiologic criteria as the experimental group for airway removal and intensive care unit discharge readiness.

    Procedure: Conventional Anesthesia Group

Interventions

  • ProcedureNonintubated Anesthesia Group

    A standardized perioperative anesthesia strategy using a supraglottic airway without routine endotracheal intubation, with early restoration of spontaneous breathing when clinically feasible. Airway management, ventilation, and perioperative care will follow predefined study procedures. Endotracheal intubation or escalation of respiratory or circulatory support will be performed whenever clinically necessary for patient safety.

  • ProcedureConventional Anesthesia Group

    A standardized perioperative anesthesia strategy using endotracheal intubation and lung-protective mechanical ventilation during cardiac surgery with cardiopulmonary bypass. Airway management, ventilation, and perioperative care will follow predefined study procedures. Extubation will be performed when predefined physiologic criteria are met, and respiratory or circulatory support will be escalated whenever clinically necessary for patient safety.

06

What researchers measure

Primary outcomes

  1. Postoperative ICU Length of Stay

    Total duration of the initial ICU admission and any ICU readmission during the index hospitalization.

    Time frame: From the end of surgery until hospital discharge or in-hospital death, assessed up to 90 days after surgery.

  2. Cumulative Duration of Postoperative Respiratory Support

    Cumulative Duration of Postoperative Respiratory Support

    Time frame: From the end of surgery through postoperative Day 30.

  3. Number of Participants With One or More Postoperative Pulmonary Complications Within 30 Days After Surgery

    Number of participants who experience at least one of the following postoperative pulmonary complications within 30 days after surgery: (1) cumulative postoperative invasive mechanical ventilation lasting more than 48 hours, calculated from the end of surgery and including both initial invasive ventilation and invasive ventilation after any subsequent reintubation; (2) unplanned reintubation after the first removal of the study airway because of respiratory failure, failure of airway protection, or another unplanned clinical indication; (3) tracheostomy performed for ongoing respiratory support or airway management; (4) moderate or severe acute respiratory distress syndrome (ARDS), according to the prespecified criteria in the endpoint definition manual; or (5) pneumonia, defined as a new or progressive pulmonary infiltrate together with the prespecified clinical, laboratory, and/or microbiological criteria in the endpoint definition manual.

    Time frame: From the end of surgery through postoperative Day 30.

Secondary outcomes

  1. Postoperative Multidimensional Recovery Assessed Using Standardized Clinical and Patient-Reported Measures

    Postoperative multidimensional recovery will be assessed using standardized clinical and patient-reported measures covering heart disease-related functional status and quality of life, cognitive status, pain, depressive symptoms, anxiety symptoms, and emotional well-being. Assessments will include the Minnesota Living With Heart Failure Questionnaire (MLHFQ), the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU), the Numerical Rating Scale (NRS) for pain, the 9-item Patient Health Questionnaire (PHQ-9), the 7-item Generalized Anxiety Disorder scale (GAD-7), and the Positive and Negative Affect Schedule (PANAS). Each instrument will be scored and analyzed separately according to its validated scoring method; scores from different instruments will not be combined into a single composite score. Changes from baseline and scores at prespecified postoperative time points will be reported, as applicable.

    Time frame: From baseline through postoperative Year 1

  2. Perioperative Anesthetic Medication Requirements

    Cumulative doses of prespecified anesthetic medications administered during the perioperative period, including intravenous and inhaled anesthetics, sedatives, opioid analgesics, and neuromuscular blocking agents. Each medication or medication class will be recorded and analyzed separately using prespecified units.

    Time frame: From the induction of anesthesia to the end of surgery.

  3. Number of Participants With Postoperative Cardiac Dysfunction

    participants who develop new or worsening postoperative low cardiac output syndrome

    Time frame: From the end of surgery through postoperative Day 30

  4. Number of Participants With Postoperative Acute Kidney Injury

    Acute kidney injury diagnosed based on the KDIGO criteria after surgery

    Time frame: From the end of surgery through postoperative Day 7

  5. Number of Participants With Major Postoperative Neurological Complications

    Number of participants who experience at least one major postoperative neurological complication, including stroke, transient ischemic attack, persistent coma, or an unprovoked seizure.

    Time frame: From the end of surgery through postoperative Day 30

  6. Number of Participants With Major Postoperative Infections

    surgical-site infection, pneumonia, bloodstream infection, urinary tract infection, or mediastinitis.

    Time frame: From the end of surgery through postoperative Day 30

  7. Number of Participants With Postoperative Hepatic Injury

    Number of participants who develop postoperative hepatic injury, defined as alanine aminotransferase or aspartate aminotransferase at least 5 times the upper limit of normal, or at least 3 times the upper limit of normal together with total bilirubin at least 2 times the upper limit of normal. Pre-existing abnormalities and clearly identified alternative causes will be excluded.

    Time frame: From the end of surgery through postoperative Day 30

  8. Number of Participants With Major Postoperative Bleeding

    Number of participants who experience major postoperative bleeding, defined as intracranial bleeding within 48 hours after surgery, reoperation for bleeding, transfusion of at least 5 units of whole blood or packed red blood cells within 48 hours, or chest-tube output of at least 2000 mL within 24 hours after surgery.

    Time frame: From the end of surgery through postoperative Day 2

  9. Number of Participants Requiring Unplanned Reoperation

    Number of participants who undergo at least one unplanned surgical reoperation because of a postoperative complication. Planned staged procedures and minor bedside procedures are excluded. Participants undergoing multiple reoperations will be counted once.

    Time frame: From the end of surgery through postoperative Day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We plan to share de-identified individual participant data (IPD) underlying the results reported in the primary publication of this clinical trial. Shared IPD may include baseline demographic and clinical characteristics, surgical procedure, randomized treatment assignment, anesthesia and airway management, ventilation and respiratory support data, perioperative interventions, protocol adherence and strategy conversion, postoperative pulmonary complications, ICU and hospital outcomes, adverse events, mortality, and other prespecified outcomes during follow-up. The study protocol, statistical analysis plan, data dictionary, and relevant analytic code will also be made available. All direct identifiers will be removed, and dates or potentially identifying variables will be shifted, aggregated, or otherwise processed as necessary to protect participant privacy.

Supporting information: Study protocol

Time frame: Beginning at study completion and ending 5 years after study completion.

Access criteria: De-identified IPD and supporting documents (study protocol, statistical analysis plan, and data dictionary) will be available to qualified researchers outside the primary study group for scientifically sound research purposes. Access will be granted upon submission of a written request that includes a brief research proposal, analysis plan, and proof of relevant ethics/IRB review if applicable. Requests will be reviewed by the study steering committee/data access committee. Approved requestors must sign a data use agreement prohibiting re-identification attempts and onward sharing, and requiring appropriate data security measures and acknowledgement of the original study. Data will be provided through a secure electronic transfer or a controlled-access online repository; access instructions will be provided after approval.

Data sharing details ↗ · www.gyfyyy.cn

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Aug 4, 2026
StartActual
Jul 21, 2026
Primary completionEst.
Jul 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07744009
Responsible party
Jianxing He (Chief Physician and Professor of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
Aug 4, 2026
Start date
Jul 21, 2026
Primary completion
Jul 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 7, 2026

Study contacts

Haoxiang Yuan Doctor
Contact
1006207119@qq.com
+8615692028041

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion